Proveca and BCWorld Healthcare announce the launch of the first licensed product in South Korea
This press release is intended for investors only
Proveca and BCWorld Healthcare announce the launch of the first licensed product in South Korea for the symptomatic treatment of severe sialorrhea in children and adolescents aged 3 years and older with chronic neurological disorders.
20 March 2026 – Proveca and BCWorld Healthcare (hereinafter BCW) are pleased to announce the launch of Sialanar® (glycopyrronium) in South Korea today. Sialanar® is the first licensed product approved in South Korea for the symptomatic treatment of severe sialorrhea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.
The South Korean launch forms part of Proveca’s international product launch programme for Sialanar®, aiming to increase access to medicines globally. Proveca is the innovator of Sialanar®, which received Paediatric-use Marketing Authorisation (PUMA) from the European Medicines Agency (EMA) and has since been launched across several European markets and more widely, including South America.
In March 2024, Proveca entered into a partnership agreement with BCW, granting BCW exclusive rights for the licensing and distribution of Sialanar® in South Korea. In October 2024, BCW subsequently submitted a New Drug Application (NDA) in South Korea for Sialanar®, with marketing authorisation granted by the Ministry of Food and Drug Safety (MFDS) in August 2025.
Glycopyrronium use is well established, with a known and predictable anticholinergic side effect profile. Adverse reactions are common with glycopyrronium due to its known pharmacodynamic anticholinergic effects. The most common adverse reactions are dry mouth (11%), constipation (20%), diarrhoea (18%), urinary retention (15%), flushing (11%) and nasal congestion (11%). Adverse reactions are more common with higher doses and prolonged use.
Full product information on Sialanar® (Prescription Only Medicine) can be found here: https://www.medicines.org.uk/emc/product/2301/smpc
Dr Simon Bryson, CEO of Proveca, said:
“We are delighted to collaborate with BCW as we continue expanding the international reach of Sialanar®. The launch in South Korea represents an important milestone in our global rollout and provides a valuable treatment option for paediatric patients with sialorrhoea. Together with BCW, we aim to help address an unmet medical need and improve the lives of more children.”
Steve Hong, CEO of BCWorld Healthcare, said:
“We are delighted to collaborate with Proveca to make Sialanar® available in South Korea. Through this collaboration, we aim to provide an additional treatment option for paediatric patients with chronic neurological conditions while continuing to expand our specialty care portfolio.”
About Proveca
Proveca Ltd is a UK-founded pharmaceutical company, with technical and commercial operations globally. The company specialises in the development, licensing and commercialisation of evidence-based medicines to address the unmet medical needs of children, with a current paediatric product portfolio in neurology and cardiology.
For more information, visit www.proveca.com
About BCWorld Healthcare
BCWorld Healthcare Co., Ltd. is a South Korea-based pharmaceutical company focused on the licensing, marketing and distribution of innovative medicines. As a subsidiary of BCWorld Pharm Co., Ltd., a KOSDAQ-listed specialty pharmaceutical company, BCWorld Healthcare supports the expansion of the group’s portfolio through global partnerships and works to improve patient access to specialised therapies in South Korea. The company also operates dedicated manufacturing facilities for sterile injectable antibiotics, including carbapenem products such as meropenem.
For more information, visit:
BCWorld Healthcare – https://bcwp.co.kr/eng/company/7
BCWorld Pharm – https://bcwp.co.kr/eng/
UK-SIA-26-0005 March 2026